FDA: Serious Liver Injury Possible with Some HCV Tx |
Clinical News
eMediNexus Coverage from: 
FDA: Serious Liver Injury Possible with Some HCV Tx

1 Read Comments                

Patients with advanced liver disease taking certain medications for hepatitis C virus (HCV) infection may be at risk for serious liver complications, including liver failure, the FDA said Wednesday.

In a statement, the agency said it had received reports linking the use of three agents for treating chronic HCV infection -- glecaprevir/pibrentasvir (Mavyret), elbasvir/grazoprevir (Zepatier), and sofosbuvir/velpatasvir/voxilaprevir (Vosevi) -- to "rare" cases of worsening liver function or liver failure in patients with moderate-to-severe liver impairment (Child-Pugh B or C)… (Medpage Today)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now